Cryptensive

    Drug Pipeline Tracker

    Which medicines are in which trial stage, by company and disease. We start with the obesity race between Eli Lilly and Novo Nordisk, the two companies that dominate it.

    Eli Lilly85 trials running51 in Phase 3, 16 in Phase 2, 18 in Phase 1, on 15 medicines
    Novo Nordisk60 trials running33 in Phase 3, 6 in Phase 2, 21 in Phase 1, on 7 medicines
    Eli Lilly: late-stage volunteers78,185People planned across its running Phase 3 trials
    Novo Nordisk: late-stage volunteers44,332People planned across its running Phase 3 trials

    The race, stage by stage

    Each medicine sits at the furthest stage it has reached for this disease. Click one to see its trials.

    Phase 1Phase 2Phase 3FiledApproved
    Eli LillyBrenipatideLY3457263LY4167586LY4174794LY4247147LY4329090MacupatideBimagrumabMazdutideNaperiglipronLY4086940EloralintideRetatrutideTirzepatideZepboundOrforglipronFoundayo
    Novo NordiskUBT251NNC0662-0419NNC0519-0130ZenagamtideCagrilintideCagriSemaSemaglutideWegovy

    Next Phase 3 results due

    The month each running Phase 3 trial expects to finish collecting its main measurements. These are the company’s own estimates; public results usually follow some months later. Next for obesity: Retatrutide, Nov 2026.

    DueMedicineTrialPeople
    Nov 2026RetatrutideTRIUMPH-5800
    Nov 2026TirzepatideSURPASS-T1D-2465
    Nov 2026TirzepatideSURPASS-T1D-1905
    Feb 2027OrforglipronADVANCE125
    Mar 2027CagriSemaA Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term609
    May 2027OrforglipronACHIEVE-RAM130
    May 2027CagrilintideRENEW 1300
    May 2027CagrilintideRENEW 2330
    May 2027CagrilintideRENEW 4285
    Jun 2027CagriSemaResearch Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema210
    Jul 2027RetatrutideTRIUMPH-8250
    Jul 2027TirzepatideA Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity344
    Aug 2027OrforglipronA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes600
    Aug 2027OrforglipronA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity800
    Aug 2027OrforglipronA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes1,400
    Aug 2027TirzepatideA Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)200
    Sept 2027RetatrutideTRIUMPH-7586
    Sept 2027OrforglipronA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1487
    Sept 2027OrforglipronA Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)974
    Sept 2027OrforglipronA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2487
    Sept 2027CagriSemaREDEFINE 37,101
    Oct 2027TirzepatideA Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)300
    Oct 2027TirzepatideSURMOUNT-MMO15,374
    Nov 2027SemaglutideFOCUS1,500
    Dec 2027OrforglipronA Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities150
    Jan 2028EloralintideENLIGHTEN-21,035
    Feb 2028BrenipatideRENEW-MDD-11,000
    Feb 2028SemaglutideOASIS 5450
    Feb 2028CagriSemaA Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight2,500
    Mar 2028EloralintideENLIGHTEN-11,980
    Mar 2028EloralintideENLIGHTEN-3800
    Mar 2028EloralintideENLIGHTEN-4900
    Mar 2028OrforglipronRESTRAIN-SUI1,000
    Mar 2028OrforglipronATTAIN-CN192
    Apr 2028RetatrutideTRIUMPH-6643
    Apr 2028OrforglipronATTAIN-OA PAIN800
    Apr 2028TirzepatideCOMMIT-UC350
    Apr 2028BrenipatideRENEW-ALC-21,100
    Apr 2028BrenipatideRENEW-ALC-11,100
    May 2028TirzepatideA Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)200
    May 2028TirzepatideCOMMIT-CD290
    Jun 2028EloralintideENLIGHTEN-6900
    Jun 2028OrforglipronATTAIN-PAD1,205
    Jun 2028CagriSemaREDEFINE1,408
    Jun 2028ZenagamtideAMAZE 12606
    Jun 2028ZenagamtideAMAZE 4300
    Jun 2028ZenagamtideAMAZE 9950
    Jul 2028ZenagamtideAMAZE 3300
    Jul 2028ZenagamtideAMBITION 71,778
    Aug 2028ZenagamtideAMAZE 2638
    Aug 2028ZenagamtideAMAZE 6400
    Aug 2028ZenagamtideAMAZE 5400
    Aug 2028CagriSemaA Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity400
    Oct 2028RetatrutideTRIUMPH-9600
    Oct 2028ZenagamtideAMAZE 7650
    Nov 2028SemaglutideSTEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss500
    Dec 2028BrenipatideRENEW-MDD- 21,000
    Dec 2028ZenagamtideAMAZE 81,000
    Jan 2029ZenagamtideAMAZE 13400
    Feb 2029RetatrutideThe Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)10,000
    Feb 2029ZenagamtideAMAZE 10400
    Apr 2029SemaglutideESSENCE1,205
    Jun 2029ZenagamtideAMAZE 11,150
    Jul 2029TirzepatideA Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)3,000
    Jul 2029ZenagamtideHF-POLARIS5,610
    Aug 2029OrforglipronATTAIN-NOW2,001
    Sept 2029CagriSemaREIMAGINEYOUNG80
    Oct 2029Eloralintide + TirzepatideAMPLIFY-12,115
    Oct 2029Eloralintide + TirzepatideAMPLIFY-21,000
    Nov 2029EloralintideENLIGHTEN-103,000
    Dec 2029TirzepatideEfficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)150
    Dec 2029SemaglutideA Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China300
    Mar 2030OrforglipronACHIEVE-PEDS170
    Mar 2030CagriSemaA Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight460
    Aug 2030RetatrutideA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)4,500
    Sept 2030ZenagamtideAMBIENCE8,500
    Aug 2031OrforglipronA Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)7,140

    Medicine by medicine

    Tirzepatide

    Approved

    Eli Lilly · LY3298176

    Dual hormone drug: GIP and GLP-1. Weekly injection.

    • ObesityApproved · Zepbound
    • DiabetesApproved · Mounjaro
    • HeartApproved · Mounjaro
    • KidneyPhase 2
    • LiverPhase 2
    • Sleep apneaApproved · Zepbound
    • Brain & addictionPhase 2
    20 running, 50 finished

    Orforglipron

    Approved

    Eli Lilly · LY3502970

    GLP-1 pill that needs no food or water rules. Daily pill.

    Lilly said in June 2026 it would apply to the FDA for type 2 diabetes too. We could not confirm that the application has been accepted, so diabetes stays at Phase 3 here.

    • ObesityApproved · Foundayo
    • DiabetesPhase 3
    • HeartPhase 3
    • KidneyPhase 3
    • Sleep apneaPhase 3
    • Knee & jointsPhase 3
    17 running, 33 finished

    Semaglutide

    Approved

    Novo Nordisk

    GLP-1 hormone drug. Weekly injection and daily pill.

    • ObesityApproved · Wegovy
    • DiabetesApproved · Ozempic
    • HeartApproved · Wegovy
    • KidneyApproved · Ozempic
    • LiverApproved · Wegovy
    • Knee & jointsPhase 3
    • Brain & addictionPhase 3
    10 running, 88 finished, 1 stopped

    CagriSema

    Filed

    Novo Nordisk · cagrilintide + semaglutide

    Two hormones in one shot: amylin and GLP-1. Weekly injection.

    • ObesityFiled
    • DiabetesPhase 3
    • HeartPhase 3
    • KidneyPhase 2
    • Brain & addictionPhase 2

    Filed with the FDA in December 2025. Novo prepares a US launch in early 2027.

    12 running, 20 finished

    Zenagamtide

    Phase 3

    Novo Nordisk · amycretin, NNC0487-0111

    One molecule that acts on both GLP-1 and amylin. Injection and pill.

    Formerly called amycretin. Its large AMAZE obesity programme is under way.

    • ObesityPhase 3
    • DiabetesPhase 3
    • HeartPhase 3
    • Sleep apneaPhase 3
    • Knee & jointsPhase 3
    22 running, 9 finished

    Eloralintide

    Phase 3

    Eli Lilly · LY3841136

    Amylin hormone drug, a different route from GLP-1. Injection.

    • ObesityPhase 3
    • DiabetesPhase 3
    • HeartPhase 3
    • KidneyPhase 1
    • Sleep apneaPhase 3
    • Knee & jointsPhase 3
    18 running, 7 finished

    Brenipatide

    Phase 1

    Eli Lilly · LY3537031

    How it works is not stated in the trial registry. Injection.

    • ObesityPhase 1
    • Brain & addictionPhase 3
    15 running, 3 finished

    Retatrutide

    Phase 3

    Eli Lilly · LY3437943

    Triple hormone drug: GLP-1, GIP and glucagon. Weekly injection.

    Lilly plans to apply to the FDA in the first quarter of 2027, after positive Phase 3 obesity trials.

    • ObesityPhase 3
    • DiabetesPhase 3
    • HeartPhase 3
    • KidneyPhase 3
    • Sleep apneaPhase 3
    • Knee & jointsPhase 3
    10 running, 22 finished

    Cagrilintide

    Phase 3

    Novo Nordisk · NNC0174-0833

    Amylin hormone drug on its own. Weekly injection.

    • ObesityPhase 3
    • DiabetesPhase 3
    • HeartPhase 1
    7 running, 10 finished

    Macupatide

    Phase 2

    Eli Lilly · LY3532226

    How it works is not stated in the trial registry. Injection.

    • ObesityPhase 2
    • DiabetesPhase 2
    4 running, 4 finished

    UBT251

    Phase 2

    Novo Nordisk

    Triple hormone drug: GLP-1, GIP and glucagon, licensed from United Laboratories. Weekly injection.

    • ObesityPhase 2
    • DiabetesPhase 2
    4 running

    NNC0662-0419

    Phase 2

    Novo Nordisk

    How it works is not stated in the trial registry.

    • ObesityPhase 2
    • DiabetesPhase 2
    4 running, 2 finished

    How a medicine gets to market

    • Phase 1: a small group, often healthy volunteers. Is it safe, and what does the body do with it?
    • Phase 2: dozens to hundreds of patients. Does it work, and at what dose?
    • Phase 3: usually thousands of patients. Is it better than placebo or an existing drug?
    • Filed: the company has applied, and the FDA is reviewing. See the FDA Decision Calendar.
    • Approved: it can be sold for that use. Each new use needs its own trials and approval.

    How to read this page

    More trials does not mean better medicines. A later stage is not a promise either: most drugs fail, even in Phase 3. A stage here is the furthest any trial has reached, not a sign that the trial succeeded, and a finished trial may have missed its goal. Companies also drop drugs without changing old records.

    Read more about the companies in our Eli Lilly and Novo Nordisk reviews. Not medical or financial advice.

    Frequently asked questions

    What is a drug pipeline?

    A company’s list of medicines still being tested, each at a stage of testing in people. Most medicines that enter trials never reach patients, so an early-stage drug is a chance, not a product.

    What are Phase 1, 2 and 3?

    Phase 1 tests safety in a small group. Phase 2 tests whether it works and at what dose. Phase 3 tests it in thousands of people, and those results go to the FDA.

    Who is ahead in the obesity race, Lilly or Novo?

    By trials running now on the medicines tracked here, Eli Lilly has 85 and Novo Nordisk has 60, of which 51 and 33 are Phase 3. More trials does not mean better medicines, and approved drugs are not compared on effect here.

    Where does this data come from?

    From ClinicalTrials.gov, a United States Government database of clinical studies. We add what the registry does not hold: how a drug works, FDA approvals and applications under review.

    How up to date is it?

    The trials refresh each time the site is rebuilt, several times a day. The data on this page was processed by ClinicalTrials.gov on 6 November 2026. Companies can be late in updating their own records.

    Are the result dates exact?

    No. The dates are when a trial expects to finish collecting its main measurements. They are estimates set by the company, and the public results usually come some months later.

    Source: ClinicalTrials.gov, a United States Government database from the National Library of Medicine. Data processed by ClinicalTrials.gov on 6 November 2026.

    What we changed: we kept interventional trials with a phase, started since 1 January 2018, led by each company, and dropped withdrawn ones. We matched trials to medicines by name and code, leaving out most trials where a medicine is only the comparison, and counted a combination under each of its new medicines. Companies’ other early candidates are not shown. We sorted trials into disease groups by keywords in their conditions and titles, so a trial can be in several, and simplified the status labels. The stage is the highest phase of trials not stopped. Approvals, filings, how each drug works and the notes on medicines are ours, from FDA and company announcements, not from ClinicalTrials.gov. The US Government does not endorse this page and gives no warranty for the data.